Literature DB >> 1349460

Weight gain among schizophrenic patients treated with clozapine.

J S Lamberti1, T Bellnier, S B Schwarzkopf.   

Abstract

A retrospective chart review was used to assess weight changes in 36 chronic schizophrenic inpatients who were treated with clozapine after being treated with standard neuroleptics. The average weight gain during 6 months of clozapine treatment was 16.9 lb; 75.0% of the patients gained at least 10 lb. The results confirm previous findings of clozapine-associated weight gain.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1349460     DOI： 10.1176/ajp.149.5.689

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  21 in total

Review 1.  Clinical profile of clozapine: adverse reactions and agranulocytosis.

Authors:  J A Lieberman; A Z Safferman
Journal:  Psychiatr Q       Date:  1992

Review 2.  Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

Authors:  David C Henderson
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 3.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents.

Authors:  David C Henderson
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

5.  Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment.

Authors:  Ric M Procyshyn; Kishor M Wasan; Allen E Thornton; Alasdair M Barr; Eric Y H Chen; Edith Pomarol-Clotet; Emmanuel Stip; Richard Williams; G William Macewan; C Laird Birmingham; William G Honer
Journal:  J Psychiatry Neurosci       Date:  2007-09       Impact factor: 6.186

6.  A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.

Authors:  D C Henderson; X Fan; B Sharma; P M Copeland; C P Borba; R Boxill; O Freudenreich; C Cather; A Eden Evins; D C Goff
Journal:  Acta Psychiatr Scand       Date:  2009-01-12       Impact factor: 6.392

7.  Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.

Authors:  David C Henderson; Xiaoduo Fan; Bikash Sharma; Paul M Copeland; Christina P C Borba; Oliver Freudenreich; Corinne Cather; A Eden Evins; Donald C Goff
Journal:  J Psychiatr Pract       Date:  2009-07       Impact factor: 1.325

Review 8.  Hyperglycemia with antipsychotic treatment.

Authors:  Roopa Sathyaprakash; Robert R Henry
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

9.  Interventions for Weight Gain in Adults Treated With Novel Antipsychotics.

Authors:  Ralph Aquila; Marianne Emanuel
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-02

10.  A Perspective on the Primary Care of Patients With Behavior, Mood, and Thought Disturbances: Clinical Applications of Olanzapine.

Authors:  Donald P. Hay; Daniel J. Hurley; Hillary C. McGuire; Linda K. Hay
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2001-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.